Drugs / CLL1 CAR-T
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07338357 | Jan 2026 → Oct 2028 expected | acute myeloid leukemia | First Affiliated Hospital of Guangxi Medical University | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05467202 | Aug 2022 → Aug 2024 | acute myeloid leukemia | Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLL-1 CAR-T | “A infusion of CLL-1 CAR-T cells following a lymphodepleting chemotherapy regimen.” NCT07338357 ↗ |
| Modality | Cell therapy | “CLL1 CAR-T” NCT05467202 ↗ |
| Route | Intravenous | “administered intravenously” NCT05467202 ↗ |